10-Q: CEL-SCI Reports Q2 2025 Results, Focuses on Multikine Confirmatory Study

CEL-SCI Corporation reports its financial results for the quarter ended March 31, 2025, highlighting its focus on advancing Multikine through a confirmatory registration study.

Summary

• CEL-SCI Corporation reported a net loss of $13.6 million for the six months ended March 31, 2025, compared to a net loss of $14.0 million for the same period in 2024.
• Research and development expenses decreased to $8.4 million from $9.0 million year-over-year.
• General and administrative expenses increased slightly to $4.8 million from $4.6 million year-over-year.
• The company's cash and cash equivalents decreased to $1.9 million as of March 31, 2025, from $4.7 million as of September 30, 2024.
• CEL-SCI is focusing on a confirmatory registration study for Multikine, targeting head and neck cancer patients with no lymph node involvement and low PD-L1 tumor expression.
• The company believes Multikine significantly extended life in the Phase III study, observing a 73% survival rate versus 45% without Multikine at 5 years after treatment in the target population.
• CEL-SCI applied to the FDA for a 212-patient randomized controlled confirmatory registration study focusing only on those patients in the target population.
• The cost of the confirmatory registration study is estimated to be about $30 million.
• The company acknowledges substantial doubt about its ability to continue as a going concern due to recurring losses and future liquidity needs.

Sentiment

Score: 4

Explanation: The sentiment is cautiously negative. While there's positive news regarding the FDA's indication to proceed with the confirmatory study and promising Phase III data, the company's financial losses, decreasing cash reserves, and going concern warning weigh heavily on the outlook.

Positives

• The FDA has indicated that CEL-SCI may proceed with a confirmatory registration study for Multikine.
• Phase III study data showed a significant survival benefit for Multikine in the target patient population (73% vs 45% at 5 years).
• The company completed a bias analysis for the target population in the Phase III study and found no bias.
• The company believes that the confirmatory study has a high likelihood of success based on the large survival benefit that has already been observed in the target population from the completed Phase III study.

Negatives

• The company reported a net loss of $13.6 million for the six months ended March 31, 2025.
• Cash and cash equivalents decreased to $1.9 million as of March 31, 2025.
• The company acknowledges substantial doubt about its ability to continue as a going concern.
• The company's disclosure controls and procedures were not effective as of March 31, 2025 due to the material weaknesses described in the Company's Annual Report on Form 10-K for the year ended September 30, 2024.

Risks

• The company's ability to raise additional capital is dependent on market conditions and is outside of its control.
• There is no assurance that the company will be successful in raising additional funds on a timely basis or that the funds will be available to the company on acceptable terms or at all.
• The company's ability to obtain regulatory approval for the sale of its products is uncertain.
• The company may have to curtail its operations if it does not raise the necessary amounts of money.

Future Outlook

CEL-SCI plans to initiate a 212-patient confirmatory registration study for Multikine, with the potential to seek early approval after full enrollment. The company's goal is to begin the confirmatory registration study as soon as the needed capital has been raised, with full enrollment about 15 months later.

Management Comments

• CEL-SCI hopes to participate in this growing market with its lead investigational therapy Multikine (Leukocyte Interleukin, Injection).
• CEL-SCI believes Multikine significantly extended life in the Phase III study.
• CEL-SCI believes that the confirmatory study has a high likelihood of success based on the large survival benefit that has already been observed in the target population from the completed Phase III study.

Industry Context

The report highlights the growing immunotherapy market and CEL-SCI's potential role in it with Multikine, particularly in addressing the unmet needs of head and neck cancer patients with low PD-L1 expression, a segment that may not be as effectively served by existing checkpoint inhibitors like Keytruda and Opdivo.

Comparison to Industry Standards

• The document mentions Keytruda and Opdivo, checkpoint inhibitors that are approved for head and neck cancer, but notes that they appear to work best in patients with high PD-L1 expression, while Multikine targets patients with low PD-L1 expression.
• The document cites a Bloomberg report estimating the global cancer immunotherapy market to reach $196.45 billion by 2030, indicating the potential market size for CEL-SCI's Multikine if approved.

Stakeholder Impact

• Shareholders face the risk of further dilution through potential capital raises.
• Employees' job security is uncertain due to the company's financial instability.
• Patients with head and neck cancer could benefit from Multikine if it receives regulatory approval.
• The company's suppliers and creditors face the risk of delayed or non-payment due to the company's financial difficulties.

Next Steps

• Begin the 212-patient confirmatory registration study as soon as the needed capital has been raised.
• Seek potential early approval after full enrollment of the confirmatory study.
• Continue to seek additional capital through corporate partnerships, debt, and/or equity financings.

Key Dates

Keywords

Multikine, CEL-SCI, Head and Neck Cancer, Immunotherapy, Clinical Trial, FDA, Financial Results, LEAPS, Research and Development, Confirmatory Study